$ cat ./records/gates-foundation-and-wellcome-fund-m72-tuberculosis-vaccine-phase-2023.txt
Gates Foundation and Wellcome Fund M72 Tuberculosis Vaccine Phase III Trial with $550 Million
[RECORD.TXT] · cat --full
The Gates Foundation and Wellcome pledged $550 million — roughly $400 million from Gates — to fund the largest tuberculosis vaccine trial in decades. The Phase III trial of the M72/AS01E candidate enrolled approximately 26,000 participants across more than 50 sites in Africa and Southeast Asia. TB kills 1.6 million people annually, and M72 showed 50 percent efficacy against active disease in an earlier Phase IIb study — the first TB vaccine to show meaningful efficacy in over a century of trying.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds Quantoom Biosciences to Halve mRNA Vaccine Production Costs
Next →
Gates Foundation Invests $40 Million to Scale mRNA Vaccine Manufacturing in Africa
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.